An update on diastolic dysfunction

Cardiology in Review

Volumn 20, Issue 5, 2012, Pages 230-236

  Lanier, Gregg M ^a   Vaishnava, Prashant ^b   Kosmas, Constantine E ^b   Wagman, Gabriel ^c   Hiensch, Robert ^b   Vittorio, Timothy J ^c  

^a WESTCHESTER MEDICAL CENTER   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c ST FRANCIS HOSPITAL   (United States)

Author keywords

diastolic dysfunction; echocardiography; heart failure; left atrial pressure; pathophysiology

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CHLORTALIDONE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLYCERYL TRINITRATE; IRBESARTAN; LISINOPRIL; MINERALOCORTICOID ANTAGONIST; MORPHINE; PLACEBO;

ANTIHYPERTENSIVE THERAPY; DIASTOLE; DIASTOLIC DYSFUNCTION; ECHOCARDIOGRAPHY; FOLLOW UP; HEART FAILURE; HEART FAILURE WITH PRESERVED SYSTOLIC FUNCTION; HEART FUNCTION; HEART LEFT ATRIUM PRESSURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART MUSCLE REVASCULARIZATION; HOSPITALIZATION; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OXYGEN THERAPY; PROGNOSIS; REVIEW;

DIURETICS; FORECASTING; HEART FAILURE, DIASTOLIC; HUMANS; MIDDLE AGED; PROGNOSIS; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84864887555     PISSN: 10615377     EISSN: 15384683     Source Type: Journal    
DOI: 10.1097/CRD.0b013e31825356d6     Document Type: Review

References (64)

1. Roger VL, Go AS, Lloyd-Jones DM, et al.; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2011 update a report from the American Heart Association. Circulation. 2011;123 e18-e209.
2. Zile MR, Gaasch WH, Carroll JD, et al. Heart failure with a normal ejection fraction is measurement of diastolic function necessary to make the diagnosis of diastolic heart failure? Circulation. 2001;104 779-782. (Pubitemid 32762675)
3. Bhatia RS, Tu JV, Lee DS, et al. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med. 2006;355 260-269. (Pubitemid 44088349)
4. Owan TE, Hodge DO, Herges RM, et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006;355 251-259. (Pubitemid 44079340)
5. Senni M, Tribouilloy CM, Rodeheffer RJ, et al. Congestive heart failure in the community a study of all incident cases in Olmsted County, Minnesota, in 1991. Circulation. 1998;98 2282-2289. (Pubitemid 28533847)
6. Redfield MM, Jacobsen SJ, Burnett JC Jr, et al. Burden of systolic and diastolic ventricular dysfunction in the community appreciating the scope of the heart failure epidemic. JAMA. 2003;289 194-202. (Pubitemid 36068707)
7. Lee DS, Gona P, Vasan RS, et al. Relation of disease pathogenesis and risk factors to heart failure with preserved or reduced ejection fraction insights from the framingham heart study of the national heart, lung, and blood institute. Circulation. 2009;119 3070-3077.
8. Vasan RS, Benjamin EJ, Levy D. Prevalence, clinical features and prognosis of diastolic heart failure an epidemiologic perspective. J Am Coll Cardiol. 1995;26 1565-1574.
9. From AM, Scott CG, Chen HH. Changes in diastolic dysfunction in diabetes mellitus over time. Am J Cardiol. 2009;103 1463-1466.
10. Kindermann M, Reil JC, Pieske B, et al. Heart failure with normal left ventricular ejection fraction what is the evidence? Trends Cardiovasc Med. 2008;18 280-292.
11. Brutsaert DL, Sys SU, Gillebert TC. Diastolic failure pathophysiology and therapeutic implications. J Am Coll Cardiol. 1993;22 318-325. (Pubitemid 23189968)
12. Leite-Moreira AF. Current perspectives in diastolic dysfunction and diastolic heart failure. Heart. 2006;92 712-718.
13. Baicu CF, Zile MR, Aurigemma GP, et al. Left ventricular systolic performance, function, and contractility in patients with diastolic heart failure. Circulation. 2005;111 2306-2312. (Pubitemid 40647065)
14. Maeder MT, Kaye DM. Heart failure with normal left ventricular ejection fraction. J Am Coll Cardiol. 2009;53 905-918.
15. Nagueh SF, Appleton CP, Gillebert TC, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. J Am Soc Echocardiogr. 2009;22 107-133.
16. Zile MR, Brutsaert DL. New concepts in diastolic dysfunction and diastolic heart failure Part II causal mechanisms and treatment. Circulation. 2002;105 1503-1508. (Pubitemid 34263285)
17. Bonow RO, Udelson JE. Left ventricular diastolic dysfunction as a cause of congestive heart failure. Mechanisms and management. Ann Intern Med. 1992;117 502-510.
18. Verma A, Solomon SD. Diastolic dysfunction as a link between hypertension and heart failure. Med Clin North Am. 2009;93 647-664.
19. van Heerebeek L, Borbély A, Niessen HW, et al. Myocardial structure and function differ in systolic and diastolic heart failure. Circulation. 2006;113 1966-1973.
20. Phan TT, Abozguia K, Nallur Shivu G, et al. Heart failure with preserved ejection fraction is characterized by dynamic impairment of active relaxation and contraction of the left ventricle on exercise and associated with myocardial energy deficiency. J Am Coll Cardiol. 2009;54 402-409.
21. Kitzman DW, Higginbotham MB, Cobb FR, et al. Exercise intolerance in patients with heart failure and preserved left ventricular systolic function failure of the Frank-Starling mechanism. J Am Coll Cardiol. 1991;17 1065-1072.
22. Zile MR, Brutsaert DL. New concepts in diastolic dysfunction and diastolic heart failure Part I diagnosis, prognosis, and measurements of diastolic function. Circulation. 2002;105 1387-1393. (Pubitemid 34260433)
23. Olsson LG, Swedberg K, Ducharme A, et al.; CHARM Investigators. Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. J Am Coll Cardiol. 2006;47 1997-2004.
24. Chinnaiyan KM, Alexander D, Maddens M, et al. Curriculum in cardiology integrated diagnosis and management of diastolic heart failure. Am Heart J. 2007;153 189-200. (Pubitemid 46096853)
25. Paulus WJ, Tschöpe C, Sanderson JE, et al. How to diagnose diastolic heart failure a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J. 2007;28 2539-2550. (Pubitemid 47614269)
26. Garcia MJ, Thomas JD, Klein AL. New Doppler echocardiographic applications for the study of diastolic function. J Am Coll Cardiol. 1998;32 865-875. (Pubitemid 28459571)
27. Muntinga HJ, van den Berg F, Knol HR, et al. Normal values and reproducibility of left ventricular filling parameters by radionuclide angiography. Int J Card Imaging. 1997;13 165-71; discussion 173.
28. Lubien E, DeMaria A, Krishnaswamy P, et al. Utility of B-natriuretic peptide in detecting diastolic dysfunction comparison with Doppler velocity recordings. Circulation. 2002;105 595-601. (Pubitemid 34123434)
29. Mottram PM, Leano R, Marwick TH. Usefulness of B-type natriuretic peptide in hypertensive patients with exertional dyspnea and normal left ventricular ejection fraction and correlation with new echocardiographic indexes of systolic and diastolic function. Am J Cardiol. 2003;92 1434-1438. (Pubitemid 37532566)
30. Zile MR, Baicu CF, Gaasch WH. Diastolic heart failure-abnormalities in active relaxation and passive stiffness of the left ventricle. N Engl J Med. 2004;350 1953-1959.
31. Daneshvar D, Wei J, Tolstrup K, et al. Diastolic dysfunction improved understanding using emerging imaging techniques. Am Heart J. 2010;160 394-404.
32. Rubinshtein R, Glockner JF, Feng D, et al. Comparison of magnetic resonance imaging versus Doppler echocardiography for the evaluation of left ventricular diastolic function in patients with cardiac amyloidosis. Am J Cardiol. 2009;103 718-723.
33. Rathi VK, Doyle M, Yamrozik J, et al. Routine evaluation of left ventricular diastolic function by cardiovascular magnetic resonance a practical approach. J Cardiovasc Magn Reson. 2008;10 36.
34. Hunt SA, Abraham WT, Chin MH, et al.; American College of Cardiology Foundation; American Heart Association. 2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation. J Am Coll Cardiol. 2009;53 e1-e90.
35. Oghlakian GO, Sipahi I, Fang JC. Treatment of heart failure with preserved ejection fraction have we been pursuing the wrong paradigm? Mayo Clin Proc. 2011;86 531-539.
36. Klingbeil AU, Schneider M, Martus P, et al. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med. 2003;115 41-46. (Pubitemid 36831120)
37. Lakhani M, Fein S. Effects of obesity and subsequent weight reduction on left ventricular function. Cardiol Rev. 2011;19 1-4.
38. Solomon SD, Janardhanan R, Verma A, et al.; Valsartan In Diastolic Dysfunction (VALIDD) Investigators. Effect of angiotensin receptor blockade and antihypertensive drugs on diastolic function in patients with hypertension and diastolic dysfunction a randomised trial. Lancet. 2007;369 2079-2087. (Pubitemid 46935945)
39. Müller-Brunotte R, Kahan T, Malmqvist K, et al. Tissue velocity echocardiography shows early improvement in diastolic function with irbesartan and atenolol therapy in patients with hypertensive left ventricular hypertrophy. Results form the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA). Am J Hypertens. 2006;19 927-936. (Pubitemid 46106993)
40. Friedrich S, Lorell B, Douglas P, et al. Intracardiac ACE inhibition improves diastolic distensibility in patients with left ventricular hypertrophy due to aortic stenosis. Circulation. 1992;86(suppl 1) 1-119.
41. Lorell BH, Grossman W. Cardiac hypertrophy the consequences for diastole. J Am Coll Cardiol. 1987;9 1189-1193.
42. Davis BR, Kostis JB, Simpson LM, et al.; ALLHAT Collaborative Research Group. Heart failure with preserved and reduced left ventricular ejection fraction in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Circulation. 2008;118 2259-2267.
43. Cleland JG, Tendera M, Adamus J, et al.; PEP-CHF Investigators. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J. 2006;27 2338-2345. (Pubitemid 44453578)
44. Hernandez AF, Hammill BG, O'Connor CM, et al. Clinical effectiveness of beta-blockers in heart failure findings from the OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure) Registry. J Am Coll Cardiol. 2009;53 184-192.
45. Flather MD, Shibata MC, Coats AJ, et al.; SENIORS Investigators. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J. 2005;26 215-225. (Pubitemid 40222359)
46. Massie BM, Nelson JJ, Lukas MA, et al.; COHERE Participant Physicians. Comparison of outcomes and usefulness of carvedilol across a spectrum of left ventricular ejection fractions in patients with heart failure in clinical practice. Am J Cardiol. 2007;99 1263-1268. (Pubitemid 46659875)
47. Yip GW, Wang M, Wang T, et al. The Hong Kong diastolic heart failure study a randomised controlled trial of diuretics, irbesartan and ramipril on quality of life, exercise capacity, left ventricular global and regional function in heart failure with a normal ejection fraction. Heart. 2008;94 573-580. (Pubitemid 351580128)
48. Ahmed A, Rich MW, Fleg JL, et al. Effects of digoxin on morbidity and mortality in diastolic heart failure the ancillary digitalis investigation group trial. Circulation. 2006;114 397-403. (Pubitemid 44264821)
49. Pitt B, Reichek N, Willenbrock R, et al. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy the 4E-left ventricular hypertrophy study. Circulation. 2003;108 1831-1838. (Pubitemid 37296092)
50. Zannad F, Alla F, Dousset B, et al. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure insights from the randomized aldactone evaluation study (RALES). Rales Investigators. Circulation. 2000;102 2700-2706.
51. Daniel K, Wells G, Fray B, et al. The effect of spironolactone on exercise tolerance and quality of life in elderly women with diastolic heart failure. Am J Geriatr Cardiol. 2003;12 131.
52. Fukuta H, Sane DC, Brucks S, et al. Statin therapy may be associated with lower mortality in patients with diastolic heart failure a preliminary report. Circulation. 2005;112 357-363. (Pubitemid 41022076)
53. Gomez-Soto FM, Romero SP, Bernal JA, et al. Mortality and morbidity of newly diagnosed heart failure treated with statins a propensity-adjusted cohort study. Int J Cardiol. 2010;140 210-218.
54. Paulus WJ, van Ballegoij JJ. Treatment of heart failure with normal ejection fraction an inconvenient truth! J Am Coll Cardiol. 2010;55 526-537.
55. Zile MR, Bourge RC, Bennett TD, et al. Application of implantable hemodynamic monitoring in the management of patients with diastolic heart failure a subgroup analysis of the COMPASS-HF trial. J Card Fail. 2008;14 816-823.
56. Holland DJ, Kumbhani DJ, Ahmed SH, et al. Effects of treatment on exercise tolerance, cardiac function, and mortality in heart failure with preserved ejection fraction. A meta-analysis. J Am Coll Cardiol. 2011;57 1676-1686.
57. Kitzman DW. Understanding results of trials in heart failure with preserved ejection fraction remembering forgotten lessons and enduring principles. J Am Coll Cardiol. 2011;57 1687-1689.
58. Badano LP, Albanese MC, De Biaggio P, et al. Prevalence, clinical characteristics, quality of life, and prognosis of patients with congestive heart failure and isolated left ventricular diastolic dysfunction. J Am Soc Echocardiogr. 2004;17 253-261. (Pubitemid 38879257)
59. Chen HH, Lainchbury JG, Senni M, et al. Diastolic heart failure in the community clinical profile, natural history, therapy, and impact of proposed diagnostic criteria. J Card Fail. 2002;8 279-287. (Pubitemid 35253198)
60. Klapholz M, Maurer M, Lowe AM, et al.; New York Heart Failure Consortium. Hospitalization for heart failure in the presence of a normal left ventricular ejection fraction results of the New York Heart Failure Registry. J Am Coll Cardiol. 2004;43 1432-1438. (Pubitemid 38496351)
61. Zhang Y, Safar ME, Iaria P, et al. Prevalence and prognosis of left ventricular diastolic dysfunction in the elderly The PROTEGER Study. Am Heart J. 2010;160 471-478.
62. Zile MR, Gaasch WH, Anand IS, et al.; I-Preserve Investigators. Mode of death in patients with heart failure and a preserved ejection fraction results from the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-Preserve) trial. Circulation. 2010;121 1393-1405.
63. Gottdiener JS, McClelland RL, Marshall R, et al. Outcome of congestive heart failure in elderly persons influence of left ventricular systolic function. The Cardiovascular Health Study. Ann Intern Med. 2002;137 631-639. (Pubitemid 35176095)
64. Halley CM, Houghtaling PL, Khalil MK, et al. Mortality rate in patients with diastolic dysfunction and normal systolic function. Arch Intern Med. 2011;171 1082-1087.